A ortic dissection (AD) is a life threatening condition associated with morbidity and mortality. According to the Centers for Disease Control and Prevention, diseases of the aorta and its branches account for 43 000 to 47 000 deaths annually in the United States. 1 Most autopsy studies suggest that the presentation of thoracic aortic disease is often death because of AD and rupture. 1,2 For those with acute thoracic aortic disease who manage to obtain medical care, the mortality is high with in-hospital mortality reported to be 25%. 3, 4 Few studies have examined the hospitalization rates of AD nationally in recent times. Previous studies were limited insofar as they included only a limited geographic area, 5,6 or data from selected high-volume centers of excellence, 3 or were not conducted recently. 4, 6 We do not know if there have been recent changes in the hospitalization rates for AD, given recent improvements in important risk factors, such as blood pressure control.
diagnostic techniques and management of AD that have been adopted in the past decade have promised to improve clinical outcomes for those who survive long enough to receive medical care. [7] [8] [9] [10] Thus, data on the recent epidemiology and outcomes associated with AD could potentially assist in quantifying the present burden of AD and effectiveness of newer interventions, as well as provide valuable data for benchmarking performance of future technologies.
Accordingly, we describe national trends in hospitalization rates of patients with AD over the last decade. We also assess short-and long-term outcomes of patients who received different management strategies, such as surgical repair, thoracic endovascular aortic repair (TEVAR), and medical therapy. To do so, we analyzed data from all Medicare Fee-for-Service (FFS) beneficiaries from 2000 to 2011.
Methods

Data Sources
We used the Medicare beneficiary denominator file from the Centers for Medicare & Medicaid Services (CMS) to identify beneficiaries aged ≥65 years who were enrolled in the FFS plan for ≥1 month from January 1, 2000, to December 31, 2011. We calculated person-years for each beneficiary to account for new enrollment, disenrollment, or death for each year of the study. We then linked this person-years file to the Medicare inpatient standard analytic file from CMS to identify all Medicare FFS beneficiaries, excluding patients receiving other forms of combined coverage, that is, Medicare Advantage who were hospitalized for AD from January 1, 2000, to December 31, 2011. These administrative claims included information on patient demographics (age, sex, and race), admission and discharge dates, and ≤10 discharge diagnoses and 6 procedure codes in 2000, increasing to ≤25 diagnoses and procedure codes in 2011 (coded by the International Classification of Diseases, Ninth Revision, Clinical Modification [ICD-9-CM]). 11, 12 However, we restricted the number of diagnoses and procedures for the 2011 data to the same as the 2010 and older years data (ie, 10 diagnoses and 6 procedure codes) to make the calculation of Hierarchical Condition Categories consistent across the study period. 13 AD hospitalization was defined as discharge from an acute-care hospital with a principal discharge diagnosis of ICD-9-CM code 441.01 or 441.03 (dissection of aorta, thoracic, or thoracoabdominal, respectively). We restricted all beneficiaries in FFS for ≥12 months and used the 1999 inpatient data for beneficiaries hospitalized in 2000. To differentiate surgical repair performed for dissection of the ascending aorta (Type A) and descending aorta (Type B), we adopted the criteria developed by Sachs et al. 14 Hospitalizations associated with surgical repair for type A AD were defined as having a principal discharge diagnosis of 441.01 or 441.03, any 1 of the following ICD-9-CM procedure codes for surgery of AD: resection of thoracic vessel or aorta with anastomosis (38. 34, 38.35) , resection of thoracic vessel or aorta with replacement (38.44, 38.45), or repair of blood vessel with synthetic or unspecified patch graft (39.57, 39.58), as well as procedure codes for either cardioplegia (39.63), valve repair (35.00-35.99), or operations on vessels of the heart (36.00-36.99, 37.0, 37.2, 37.31-37.90, 37.93-37.99). To isolate type B AD, the aforementioned diagnosis codes for AD and procedure codes for surgery of AD excluding procedure codes for cardioplegia, valve repair, and operations on vessels of the heart were used. We defined hospitalizations in which the patient underwent TEVAR as both principal discharge diagnosis of 441.01 or 441.03 and ICD-9-CM procedure code for endovascular implantation of graft in thoracic aorta (39.73). Finally, hospitalizations receiving medical management were identified as having a primary discharge diagnosis of AD (441.01 or 441.03) with no accompanying procedure codes for surgery for AD or TEVAR. We excluded beneficiaries if they were hospitalized for AD outside of the 50 US states, the District of Columbia, Puerto Rico, and other US territories.
Patient Characteristics and Comorbidities
We examined the demographic and clinical characteristics of patients with AD over time. Demographic variables included age (65-74, 75-84, ≥85 years), sex, and race (white, black, and other). We determined race using the Medicare denominator file, which is based on data from the Social Security Administration. 15 We identified common comorbidities that are included in the publicly reported CMS 30-day mortality measures for acute myocardial infarction, heart failure, and pneumonia. [16] [17] [18] Specifically, we identified comorbidities using the secondary diagnosis codes from the index AD hospitalization, including those that did not represent a potential complication of care, as well as principal and secondary diagnosis codes of all hospitalizations ≤1 year before the index AD hospitalization (Appendix I in the Data Supplement). The 1999 inpatient data were used to obtain comorbidity information on patients who were hospitalized for AD in 2000. Data on TEVAR are presented from 2005 to 2011, as the ICD-9-CM procedure code for TEVAR (39.73) was first introduced in the fourth quarter of 2005.
Primary Outcomes
There were 2 main primary outcomes: hospitalization for AD and mortality. Because Medicare FFS beneficiaries were enrolled throughout the year, some beneficiaries were in FFS for the entire year, whereas others were in FFS for a few months. Thus, we calculated person-years for each beneficiary to account for new enrollment, disenrollment, or death during an index year (eg, if a beneficiary enrolled in FFS for 3 months, this beneficiary contributed 3/12 person-years into the calculation). All Medicare beneficiaries who had >1 month of enrollment in the FFS plan were included in the person-years calculation.
The hospitalization rate was calculated separately for each year by dividing the total number of AD hospitalizations in a year by the corresponding person-years for that year.
To calculate 30-day and 1-year mortality outcomes, we identified all AD hospitalizations that occurred in a given year. If a patient had >1 AD hospitalization during the study period, the initial hospitalization was selected. We adopted this approach because additional hospitalizations might reflect manifestations of the initial disease process. Additionally, we examined all-cause hospitalizations 1 year before the index hospitalization for AD to rule out prior hospitalizations for AD. The admission date of the AD hospitalization was the time zero for 30-day and 1-year mortality analyses. For hospitalizations in which the patient underwent either surgical repair or TEVAR of the dissection, the date of the procedure was considered as time zero for determining 30-day and 1-year mortality associated with that hospitalization. The 2012 Medicare enrollment file was used to obtain mortality information for patients who were hospitalized for AD in 2011.
Statistical Analysis
Changes in patient characteristics and primary outcomes (AD hospitalization and mortality rates) were examined over time. We used the Mantel-Haenszel chi-squared test to evaluate whether these changes
WHAT IS KNOWN
• There is a high mortality rate associated with aortic dissection. Less invasive interventions, such as thoracic aortic endovascular repair, have emerged for the management of complicated aortic dissection.
WHAT THE STUDY ADDS
• Hospitalization rates for aortic dissection have remained unchanged in the last decade. • The mortality associated with aortic dissection, though high, has improved in recent times. • Real world data on new interventions, such as thoracic endovascular aortic repair, for future benchmarking purposes.
over time were statistically significant. We stratified trends in hospitalization rate by age, sex, and race, and trends in both hospitalization and mortality by choice of management strategy. We fitted a linear mixed-effects model with a Poisson link function and state-specific random intercepts to assess rates of hospitalization for AD adjusted for age, sex, and race. We considered the AD hospitalization rate during 2000 as the reference and calculated the incidence rate ratio for each subsequent year by including dummy variables for the subsequent years in the mixed-effects model.
To obtain annual mortality rates adjusted for patient demographics and comorbidities, we fitted a linear mixed-effects model with a logit link function and hospital-specific random intercepts. Using data from 2000 as the referent and dummy variables for each subsequent year, we calculated the adjusted odds ratio for mortality for subsequent years. Using the method described by Zhang and Yu, we converted the odds ratio values to risk ratio estimates. 19 We then multiplied the risk ratio for each year by the mortality rate in the baseline year (2000) to calculate the adjusted mortality rates across years.
We conducted the analyses using SAS version 9.3 64-bit Windows version (SAS Institute Inc., Cary, North Carolina). All statistical testing was 2-sided, and P<0.05 was considered statistically significant. Institutional review board approval was obtained through the Yale University Human Investigation Committee.
Results
Patient Characteristics
The final sample consisted of 353 442 679 observations, representing 79 278 075 beneficiaries aged ≥65 years with ≥1 month of enrollment in Medicare FFS during the study period (336 781 989 person-years), leading to 32 057 hospitalizations for AD from 2000 to 2011. Demographic and clinical characteristics of the patients hospitalized with AD are presented in Table 1 . The mean age of hospitalized AD patients increased slightly from 77.1 years in 2000 to 77.4 years in 2011. In addition, there was a slight increase in the proportion of female patients (47.4%-51.9%) and decrease in the proportion of white patients (87.0%-83.2%) over time. The prevalence of many of the comorbidities remained relatively stable. However, certain conditions, such as hypertension (65.0%-71.5%), diabetes mellitus (8.9%-13.9%), dementia (3.8%-7.3%), renal failure (3.0%-9.2%), pneumonia (8.5%-12.6%), respiratory failure (2.1%-5.1%), and depression (3.3%-6.5%), increased. Prior literature demonstrates that the profile of patients with chronic cardiovascular conditions, such as heart failure, has become sicker with significant increase in the age and proportion of chronic comorbidities over the last decade. 12 Hence, the aforementioned temporal changes in comorbidities are most likely real versus more intense coding practice patterns.
Overall, patients who underwent an invasive repair procedure were, on average, younger than other AD patients receiving medical therapy. The mean age of patients undergoing surgical repair for type A dissection was 73. Table 2 ). Fewer women received surgical repair for type A dissection (43.5% in 2011) or TEVAR (46.9% in 2011) compared with men across the study period, despite an increase in the proportion of female AD patients over time (Table 2 ). Finally, patients receiving medical therapy were also noted to have significantly more comorbidities (hypertension, prior history of unstable angina, myocardial infarction, congestive heart failure, chronic obstructive pulmonary disease, stroke) compared with patients receiving an invasive procedure (Appendices II-V in the Data Supplement).
Hospitalization for Aortic Dissection
The overall AD hospitalization rate remained stable at 10 per 100 000 person-years across the study period (Table 3) . Trends in hospitalization rates were relatively flat for all age, sex, and race subgroups. Over time, AD hospitalization rates remained higher in older persons (particularly those aged 75-84 years), men, and blacks. Hospitalization rates based on individual management strategies are highlighted in Table 3 . The hospitalization rate for different management strategies as a percentage of AD hospitalizations are presented in Figure 1 . In summary, percentage of hospitalizations for surgical repair of type A AD remained constant, whereas hospitalizations for type B AD were increasingly supplanted by TEVAR starting in 2005 (Figure 1) . Results were substantively similar after adjusting for age, sex, and race.
Mortality Outcomes
Trends in observed mortality for all treatment arms are presented in Table 4 . Overall, for patients hospitalized with AD, there were substantial declines in observed mortality. Between 2000 and 2011, 30-day mortality declined 9.3% (95% CI, 8.3-10.2), from 31.8% to 25.4%, and 1-year mortality declined 6.4% (95% CI, 5.7-6.9), from 42.6% to 37.4%. Reductions in mortality were also observed in the subgroup of patients who underwent surgical repair for type A dissections by day 30 (9.3%; 95% CI, 8.3-10.2) and by 1 year after surgery (8.3%; 95% CI, 7.5-9.1), for surgical repair of type B dissections by day 30 (3.9%; 95% CI, 3.5-4.2) and 1 year (3.9%; 95% CI, 3.3-4.3) and finally for medical management subgroup as well by day 30 (3.9%; 95% CI, 3.8-4.1) and 1 year (2.4%; 95% CI, 2.3-2.7).
In contrast, among the limited number of patients who underwent TEVAR, 30-day mortality changed from 9.5% in 2005 to 13.9% in 2011 (P=0.4 for trend) and 1-year mortality changed from 16.7% in 2005 to 25.8% in 2011 (P=0.3 for trend), respectively. Though an increase in mortality was observed from 2005 to 2011, the changes did not meet criteria for significance.
The declines in 30-day and 1-year mortality noted in the overall group hospitalized with AD undergoing surgical repair and receiving medical therapy remained significant after adjusting for age, sex, race, and comorbidities. Between 2000 and 2011, adjusted 30-day mortality rates decreased by 5.2% (95% CI, 5.1-5.2) among all patients hospitalized with Figure 2) . Similarly, adjusted 1-year mortality rates decreased by 6.2% (95% CI, 5.3-6.7) among all hospitalized AD patients, by 8.2% (95% CI, 6.7-9.1) in the surgical repair for type A dissection subgroup, by 3.9% (95% CI, 2.5-6.3) in the subgroup of patients who underwent surgical repair for type B dissection, and by 4.0% (95% CI, 2.6-4.9) in the subgroup of patients who underwent medical management (Figure 3 ). Adjusted rates for 30-day and 1-year mortality after TEVAR could not be reliably calculated because of small numbers.
Discussion
Using national data for all Medicare FFS beneficiaries, we found that the hospitalization rate for AD has remained steady over the last decade. There has been a continued decline in both short-term mortality as well as long-term mortality rates in the overall group of patients hospitalized with AD, in the subgroup of patients undergoing surgical repair, and being managed medically. Thoracic endovascular aortic repair has become an increasingly used therapeutic option across the study period. There has been no significant change in shortand long-term mortality associated with TEVAR. Previous studies have reported AD incidence rates of 2 to 5 per 100 000 persons per year in samples of all age groups. [4] [5] [6] However, given that AD is predominantly a condition of the All the hospitalizations were counted in the hospitalization analysis but only 1 hospitalization (the initial one) was counted for those patients who had >1 hospitalization in the mortality analysis to avoid multiple counting of deaths. elderly, the hospitalization rate nationally in older persons as measured in our study was ≈10 per 100 000 person-years and remained stable across the study period. Hypertension has traditionally been recognized as an important risk factor for AD. Although nationally the prevalence of hypertension has remained stable during this period, there has been improved control of blood pressure with antihypertensive therapy. 20 Yet, a concomitant decrease in hospitalization rates for AD was not noted in our study. This may partly be because of advancements in noninvasive diagnostic technology, such as the development of multidetector CT resulting in rapid high definition CT angiography from neck to abdomen, leading to increased detection of dissection. 8, 21 Alternatively, increased prevalence of AD could be indicative of the contribution of other important etiologies of AD, namely congenital cardiovascular conditions, such as bicuspid aortic valve, familial conditions affecting the connective tissue like Marfan's Syndrome, Ehler-Danlos Syndrome, Turner Syndrome, or increased drug use, for example, cocaine/amphetamine. 22 Males were at higher risk of hospitalization compared with females. Women were less likely to receive invasive procedures compared with men. These findings are consistent with prior literature, and a potential explanation for this difference could be the increased age of women and comparatively sicker clinical presentation compared with men that could preclude the use of invasive procedures in women. 23 Even in our study, the subgroup being managed medically was older and had a higher percentage of females compared with the subgroup receiving invasive management (Table 2) . Finally, black patients were more likely to be hospitalized with a dissection compared with other racial groups. The reason for this increased susceptibility is unclear and could be from higher prevalence and severity of uncontrolled hypertension or fundamental differences in their genetic profile. 20, 22 With regards to management strategy, the hospitalization rate associated with surgical repair for type A dissection remained relatively stable throughout the study period. However, hospitalization rates for surgical repair for type B dissection were noted to decrease during the study period concomitant with an increase in hospitalization rate for TEVAR. This is likely secondary to the widespread uptake of endovascular repair as a viable therapeutic alternative for patients who were previously considered to be high risk for an open surgical intervention. We observed improvements in both short-term and longterm outcomes among patients undergoing surgical repair (for type A and type B dissections) during the study period. In the setting of a type A dissection, surgical repair is the treatment of choice and is usually performed as an emergent, life-saving procedure. In contrast, surgical repair for type B dissections is only indicated in patients with complicated presentations (impending rupture, hypotension, signs of malperfusion, or refractory hypertension). 24 Although a singular technological breakthrough in the operative management of this condition has not taken place in the last decade, subtle improvements on various fronts have been made. Advancements such as use of sophisticated neuroprotection techniques, development of improved intraoperative and postoperative pharmacological therapy, use of operative algorithm and standardized cannulation techniques, and development of care teams could all have possibly contributed toward improving mortality rates. 1, 3, 7, 9, 10, [25] [26] [27] [28] Additionally, part of the improvement in mortality seen with type B dissection could be possible because of the increasing use of the endovascular approach in the treatment of surgically high-risk patients.
On the other hand, 70% of type B dissections are managed medically with intensive antihypertensive therapy. For complicated cases, endovascular repair has evolved as a novel therapeutic alternative to surgical repair. 24 Multiple small clinical trials at high-volume centers as well as analysis of observational data from multicenter registries have been performed, evaluating the effectiveness of this as an alternative to surgical management. 14, 29, 30 Based on the mortality benefit observed in these studies, a recent expert consensus statement has recommended TEVAR as initial therapy for acute complicated type B dissections. 1, 24, 31 Thus, the availability of a less invasive modality for treatment of acute complicated dissection of the descending aorta, perhaps, explains the increasing adoption of this procedure nationally in spite of the absence of large, multisite randomized clinical trials, which have been difficult to conduct in this high-risk patient population. The 30-day mortality for TEVAR ranged from 6.2% to 13.9% in our study. This is consistent with the 30-day mortality rate (9.1%) reported by Conrad et al 32 from a similar patient population, early mortality rate (10.2%) reported by Fattori et al 24 in the recent multidisciplinary expert consensus document on the management of type B dissection, and the 30-day mortality rate (10.8%) reported by White et al 33 in their report produced in collaboration with the United States Food and Drug Administration for benchmarking future performance of this new technology.
Previous data on long-term outcomes after TEVAR are scarce 34 with 5-year survival rate in the Medicare population noted to be ≈58%. 32 The 1-year mortality rate after this procedure, as observed in our study, ranged from 16.7% to 25.8% during the study period. Because the TEVAR mortality was unadjusted given low procedure numbers, it is difficult to comment on the cause of the year-to-year fluctuations in mortality rate. These observations could be confounded by the expansion of indications for TEVAR from thoracic aneurysm repair to repair of acute high-risk AD patients recently. Other possible explanations of changing mortality over time could be indicative of rapid adoption of the procedure outside of high-volume centers of excellence to centers with less experience, although we acknowledge this is speculative.
Finally, improved short-and long-term mortality outcomes were observed in the subgroup of patients receiving medical therapy. Based on the known epidemiology of AD, the majority of the patients in this subgroup would seem to have a dissection in the descending aorta and are being managed medically. It also includes patients with dissections in the ascending aorta where surgery is contraindicated given high surgical risk. Hence, lack of procedure could be a marker of higher risk. Based on the presence of comorbidities, patients receiving medical therapy consistently appeared to be older and had a sicker profile compared with the subgroup of patients receiving invasive therapy. However, lack of information regarding the kind of medical therapy administered as well as precise clinical picture on presentation results in difficulties interpreting the results of this subgroup of patients with certainty.
There are several limitations to the present study. As our analysis was limited to Medicare FFS beneficiaries, we cannot comment on trends in patients <65 years of age or patients enrolled in Medicare Advantage programs. Although we adjusted for available potential confounders, it is possible that changing characteristics of the FFS population were not accounted for by available data. A Cox model may have been an appropriate alternative to logistic regression for the 1-year outcome analyses. However, the large sample size of our data (eg, >3000 hospitals) limited our ability to fit a Cox model with hospital-specific intercepts using SAS. Because 1-year mortality was counted from the date of admission and all patients were in the FFS program during the follow-up period (ie, no patient was lost except a death event), we took an alternative approach, which was to first fit a mixed-effects model with a logit link function and hospital-specific intercepts to obtain adjusted odds ratios of annual changes in mortality rates and then convert the adjusted odd ratios to risk ratios using the Zhang and Yu method. Although this method has been used widely over the last decade, it may be an oversimplification, 35 and alternative methods 36, 37 could be used when data do not fit well with the Zhang and Yu method. Using claims data, we were unable to differentiate if the presentation of AD was acute versus subacute (ie, incidental finding on radiographic imaging) or if TEVAR was being performed for type A versus type B dissection. This is important because it could affect our outcome estimates. Additionally, we do not account for the effect of patients crossing over from 1 treatment strategy to another (ie, medical to TEVAR/surgical repair) on outcomes, such as mortality. However, this number was noted to be <2% (Appendix VI in the Data Supplement).
Conclusions
We have attempted to define the current landscape of AD in an elderly population. Although the hospitalization rates for the disease have been stable over the last decade, a consistent decrease in mortality was observed with management of AD. Improvement in outcomes has been particularly marked in the subgroup undergoing surgical repair (both type A and type B repair) and medical therapy across the study period.
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